GLOW+ is the higher-strength GLOW blend: 100 mg GHK-Cu with 10 mg BPC-157 and 10 mg TB-500, freeze-dried together in a single 120 mg vial. The three peptides are studied in skin and connective tissue models, covering collagen production, tissue structure, and how skin cells move and multiply. It is supplied for researchers testing several pathways together rather than one at a time.
The numbers that define GLOW+ and how it is being studied. For laboratory research use only.
3
Synergistic Pathways
VEGF + Actin + Collagen
7×
GHR Upregulation (BPC-157)
Tendon fibroblast culture, day 3
4000+
Genes Modulated (GHK-Cu)
Up- or down-regulated in human cell lines
2-3×
Cell Migration (TB-500)
Keratinocytes in a Boyden chamber assay
How It Works
How GLOW+ works
The pathways GLOW+ acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
VEGF Pathway
BPC-157
Vessel formation, tissue granulation and nitric oxide signalling have been measured as endpoints in preclinical models.
Vessel formation measured
Tissue granulation scored
Modulates nitric oxide signaling
Actin Regulation
TB-500
Cell migration, cytoskeletal remodelling and fibrotic scarring are measured via the thymosin beta-4 pathway.
Cell migration measured
Cytoskeletal remodelling observed
Fibrotic scarring scored
Collagen & ECM Remodeling
GHK-Cu
Type I and III collagen synthesis measured, expression changes reported across 4,000+ genes, and copper delivered to tissue during extracellular matrix turnover.
Type I & III collagen measured
Modulates 4,000+ genes
Delivers copper to tissue
Uses & Applications
What GLOW+ is researched for
The main areas GLOW+ is being studied for - and the study-reported figures behind them.
Dermal
Dermal Models
GHK-Cu is studied for collagen synthesis; BPC-157 and TB-500 in epithelial and scarring models.
Mechanistic
Cytoskeletal & Vascular
TB-500 is characterised for actin remodelling; tendon fibroblast viability is measured for BPC-157; vascularisation endpoints for GHK-Cu.
Matrix
Anti-Inflammatory
All three peptides demonstrate anti-inflammatory properties through different mechanisms in animal models.
Structural
ECM Remodeling
Extracellular matrix deposition and fibrotic scoring as combined endpoints.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
GHK-Cu Collagen Synthesis70%
TB-500 Wound Closure Rate61%
BPC-157 GHR Expression700%
Figures are representative of published research findings and shown for reference.
Molecular Structure
The GLOW+ molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Molecular model
Sequence length
blend
Physical form
Lyophilized Powder
Documented purity
≥99% by HPLC
Compound Information
Full specification
Components
GHK-Cu 100mg + BPC-157 10mg + TB-500 10mg
Strength
120mg
Form
Lyophilized powder
Purity
≥99% by HPLC-UV (99.89% on lot 377PG1)
Testing
Third-party HPLC-UV purity, LC-MS identity, net content per peptide
Storage
-20°C for long-term stability
Light sensitivity
Protect from direct light at all times
Solubility
Water-soluble
COA
Included with every order
Appearance
Blue lyophilized powder
Stability
24 months from manufacture date when stored properly
FAQ
Common questions about GLOW+
GLOW+ is a research peptide blend of three peptides in one 120 mg vial: 100 mg GHK-Cu (copper peptide), 10 mg BPC-157 (Body Protection Compound) and 10 mg TB-500 (Thymosin Beta-4). Each is characterised on a different pathway: collagen synthesis, vascular, and cell migration respectively.
Same three peptides, different strength. GLOW+ is a 120 mg vial weighted toward GHK-Cu (100 mg), with 10 mg each of BPC-157 and TB-500. GLOW is the 70 mg vial.
In preclinical research, vessel formation (angiogenesis) is measured for BPC-157, cell migration via actin regulation for TB-500, and collagen production plus expression changes across 4,000+ genes for GHK-Cu. The three cover distinct pathways, which is the rationale for combining them.
No. GLOW+ is not approved by the FDA for any medical use. It is sold exclusively for in vitro laboratory research purposes. The individual components have varying levels of preclinical evidence but no completed human clinical trials for the combined blend.
Store lyophilized (powder) form at -20°C for maximum stability. Protect from direct light at all times and avoid repeated freeze-thaw cycles.
Every lot is tested by an independent US laboratory: HPLC-UV for purity, LC-MS to confirm the identity of each peptide, and net content per peptide. The current lot (377PG1) reads 99.89% purity with GHK-Cu 95.78 mg, BPC-157 10.43 mg and Thymosin Beta-4 9.85 mg per vial. The certificate is linked on this page.
The rationale is based on individual component research in preclinical models. The combined blend has not been characterised as a single formulation. Complementarity is inferred from mechanism.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
